- HOME
- Vol.44 No.11
- CLINICA NEUROL, 44: 771|774, 2004
- Vol.44 No.11 contents
The 45th Annual Meeting of the Japanese Society of Neurology
Biomarkers of Alzheimer's disease
Mikio Shoji, M.D., Ph. D.
Department of Neurology, Neuroscience, Biophysiological Science, Okayama University Graduate School of Medicine and Dentistry
Recent researches of CSF biomarkers, such as combinations of tau, Aβ40, Aβ42, are now establishing clinical evidence. These specific biomarkers should be used in clinical practice. To detect incipient AD form MCI and very early AD, these CSF biomarkers are quite useful. Newly developing biomarkers, such as phosphorylated tau and plasma Aβ, must be established by large scale prospective study and autopsy-correlations. Thus, the contribution of these biomarkers is desired for diagnosis and clinical practice for Alzheimer's disease.
(CLINICA NEUROL, 44: 771|774, 2004)
key words: Alzheimer's disease, Aβ40, Aβ42, tau, CSF
(Received: 12-May-04)